.. only:: not latex

    .. _citations:

    Bibliography
    ##############

    .. rubric:: References

.. comment
    citations are in alphabetical order (maintained manually!)
    
..  comment
    used Bauer as ref for following paper, because Beal was not alive in 2009.
    
.. [Bauer2009] 
    Beal, S., Sheiner, L.B., Boeckmann, A., & Bauer, R.J.
    NONMEM User's Guides. (1989-2009), Icon Development Solutions, Ellicott City, MD, USA, 2009. 
    
.. [Cheung2015]
    Amy Cheung, 
    Predictive QT project, 
    DDMODEL 0000093, 2015, (repository.ddmore.eu/model/DDMODEL00000093). 
    
.. [Christensen1980]
    Finn Norring Christensen, Flemming Yssing Hansen and Helle Bechgaard
    Physical interpretation of parameters in the Rosin-Rammler-Sperling-Weibull distribution for drug release from controlled release dosage forms
    Journal of Pharmacy and Pharmacology, Volume 32, Issue 1, September 1980, pp 580-582
    
.. comment
    CookBies only referenced in disease progression - which is not currently included.
    .. [CookBies2016] 
        Cook S.F., Bies R.R. 
        Disease Progression Modeling: Key Concepts and Recent Developments. 
        Curr Pharmacol Rep 2:221-230, 2016


.. [DennisSchnabel1987]
    J. E. Dennis, Jnr. and R. B. Schnabel
    Numerical Methods for Unconstrained Optimization and Nonlinear Equations
    Society for Industrial and Applied Mathematics
    ISBN-10: 0898713641
        
.. [Germovsek2017]
    Eva Germovsek, 
    Population PK model for gentamicin, 
    DDMODEL 0000238, 2017, (repository.ddmore.eu/model/DDMODEL00000238).
        
.. [Harling2015]
    Kajsa Harling
    Population PK of gentamicin in cancer patients with time-varying covariates, 
    DDMODEL 0000061, 2015, (repository.ddmore.eu/model/DDMODEL00000061). 
        
.. [Holford1996]
    N. H. Holford,
    A size standard for pharmacokinetics.
    Clin Pharmacokinet. 1996 May; 30(5):329-32.
        
.. [KarlssonSheiner1993]
    Karlsson MO and Sheiner LB
    The importance of modeling interoccasion variability in population pharmacokinetic analyses.
    J Pharmacokinet Biopharm. 1993 Dec; 21(6):735-50.
    
.. [Lindstrom1990]
    L Lindstrom, M & Bates, Mark. (1990). Nonlinear Mixed Effects Models for Repeated Measures Data. Biometrics. 46. 673-87. 10.2307/2532087. 
        
..  comment
    M-M example for advan10 not included, so NOT cited, move to emax examples?!?!?!
    .. [Michaelis1913] Michaelis, L.,and Menten, M. (1913) Die kinetik der invertinwirkung, Biochemistry Zeitung 49, 333-369.

.. [Millar2011]
    Russell B. Millar
    Maximum Likelihood Estimation and Inference - With Examples in R, SAS, and ADMB
    John Wiley & Sons, 2011

.. [MouldUpton2012] 
    D. R. Mould and R. N. Upton 
    Basic Concepts in population Modeling, Simulation, and Model-Based drug development
    CPT Pharmacometrics Syst Pharmacol. 2012 Sep; 1(9): e6.

.. [MouldUpton2013] 
    D. R. Mould and R. N. Upton 
    Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.
    CPT Pharmacometrics Syst Pharmacol. 2013 Apr 17; 2: e38. 

.. [NocedalWright2006]
    J. Nocedal and S. Wright
    Numerical Optimization
    Springer
    ISBN-10: 0387303030

.. [Piotrovskii1987]    
    Vladimir K. Piotrovskii
    The use of Weibull distribution to describe thein vivo absorption kinetics
    Journal of Pharmacokinetics and Biopharmaceutics, Volume 15, Issue 6, December 1987, pp 681–686
    
.. [Radhakrishnan1994]
    Radhakrishnan, Krishnan & C. Hindmarsh, Alan. (1994). Description and Use of LSODE, the Livermore Solver for Ordinary Differential Equations. 
  
..  comment
    Just use Phil's citation
    .. [Rowland2011]
        Rowland, M & Tozer, RN (2011) Clinical Pharmacokinetics  4th ed., Lippincott Williams & Wilkins.
    
.. [RowlandTozer2012]
    M. Rowland and T. N. Tozer
    Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications
    Lippincott Williams & Wilkins, 2012
    
.. [Sheiner1980] 
    Sheiner L.B., Beal S.L. 
    Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. 
    J. Pharmacokinet. Biopharm 86553–571.1980 
  
..  comment
    not referenced anywhere
    .. [TodEtAl2001]
    Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O and Aujard Y.    
    Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.
    Antimicrob Agents Chemother. 2001 Jan; 45(1):150-7.
  
.. [UptonMould2013]
    R. N. Upton and D. R. Mould
    Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods
    CPT Pharmacometrics Syst Pharmacol. 2014 Jan; 3(1): e88.
  
.. [Wang2007]
    Wang, Yaning. (2007). Derivation of various NONMEM estimation methods. Journal of pharmacokinetics and pharmacodynamics. 35. 249. 10.1007/s10928-008-9083-7. 
